Explore a curated snapshot of registered cell and regenerative-medicine studies, then continue to the official registry to confirm recruitment, eligibility and study-site details.
Registry snapshot checked 8 November 2026. Study-wide and individual-site status may differ. A listing does not establish safety, effectiveness, endorsement or eligibility.
Curated registry records
-
NCT06944522: exPDite-2: Bemdaneprocel for Parkinson's disease
Parkinson disease | Phase 3 | Recruiting
Sponsor: BlueRock Therapeutics. Countries: Australia + Canada + United States. Study locations: 43 registry-listed locations; see official record for site status. Registry last updated: 2026-11-02.
-
NCT03887273: Q-Cells glial progenitor cells for transverse myelitis
Transverse myelitis | Phase 1 / Phase 2 | Recruiting
Sponsor: Q Therapeutics, Inc.. Countries: United States. Study locations: University of Texas Southwestern Medical Center, Dallas. Registry last updated: 2026-07-21.
-
NCT06841770: Delivery-device safety study for LCTOPC1 in spinal cord injury
Spinal cord injury | Phase 1 | Recruiting
Sponsor: Lineage Cell Therapeutics, Inc.. Countries: United States. Study locations: Rancho Research Institue, Downey; University of California, San Diego, La Jolla. Registry last updated: 2026-02-12.
-
NCT07339111: CARTISTEM for knee cartilage lesions and osteoarthritis
Knee osteoarthritis | Phase 3 | Recruiting
Sponsor: Medipost, Inc.. Countries: United States. Study locations: 37 registry-listed locations; see official record for site status. Registry last updated: 2026-11-05.
-
NCT06145035: CATO: intravenous umbilical-cord stromal cells in ischemic cardiomyopathy
Ischemic cardiomyopathy | Phase 2 | Recruiting
Sponsor: Roberto Bolli. Countries: United States. Study locations: University of Miami Miller School of Medicine, Miami; University of Louisville School of Medicine, Institute of Molecular Cardiology, Louisville; The Texas Heart Institute Houston Texas, Houston. Registry last updated: 2026-05-13.
-
NCT04356287: Umbilical-cord stromal cells in systemic sclerosis
Systemic sclerosis | Phase 1 / Phase 2 | Recruiting
Sponsor: Marie Hudson, MD. Countries: Canada. Study locations: Sir Mortimer B. Davis Jewish General Hospital, Montreal. Registry last updated: 2026-02-03.
-
NCT07015983: Breakfree-SLE: CD19-targeted CAR T cells for active lupus
SLE and lupus nephritis | Phase 2 | Active, not recruiting
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Countries: Argentina + Austria + Belgium + Brazil + Canada + Denmark + France + Germany + Israel + Italy + Japan + Poland + Portugal + Spain + United Kingdom + United States. Study locations: 97 registry-listed locations; see official record for site status. Registry last updated: 2026-08-03.
-
NCT07487467: Autologous adipose stromal vascular fraction for type 2 diabetes
Type 2 diabetes | Not applicable | Recruiting
Sponsor: Kaiser Clinic and Hospital. Countries: Brazil. Study locations: Kaiser Clinica, São Jose Do Rio Preto. Registry last updated: 2026-03-23.
-
NCT06242379: MSC-derived extracellular vesicles for retinitis pigmentosa
Retinitis pigmentosa | Phase 1 / Phase 2 | Recruiting
Sponsor: Mahidol University. Countries: Thailand. Study locations: Siriraj Hospital, Bangkok Noi. Registry last updated: 2025-05-15.
-
NCT04945018: iPSC-derived cardiomyocyte spheroids for severe ischemic heart failure
Ischemic heart failure | Phase 1 / Phase 2 | Completed
Sponsor: Heartseed Inc.. Countries: Japan. Study locations: 8 registry-listed locations; see official record for site status. Registry last updated: 2026-10-22.
-
NCT04689152: Cellgram-LC for alcohol-related liver cirrhosis
Liver cirrhosis | Phase 3 | Recruiting
Sponsor: Pharmicell Co., Ltd.. Countries: South Korea. Study locations: 15 registry-listed locations; see official record for site status. Registry last updated: 2026-09-21.
-
NCT06491043: Umbilical-cord MSC infusion for moderate to severe COPD
COPD | Phase 2 | Recruiting
Sponsor: Meribank Biotech Co., Ltd.. Countries: Taiwan. Study locations: Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare, New Taipei City; Chang Gung Memorial Hospital, Linkou, Taoyuan City. Registry last updated: 2024-07-08.
-
NCT06129175: Neuroncell-EX for acute ischemic stroke
Acute ischemic stroke | Phase 2 / Phase 3 | Recruiting
Sponsor: Cytopeutics Sdn. Bhd.. Countries: Malaysia. Study locations: Hospital Canselor Tuanku Muhriz UKM, Cheras. Registry last updated: 2026-01-02.
-
NCT07396155: Umbilical-cord MSC therapy in diabetic nephropathy
Diabetic nephropathy | Phase 1 / Phase 2 | Recruiting
Sponsor: PT. Prodia Stem Cell Indonesia. Countries: Indonesia. Study locations: Dr. Sardjito General Hospital, Yogyakarta. Registry last updated: 2026-02-09.
-
NCT07652632: Autologous stromal vascular fraction for refractory perianal Crohn's disease
Crohn's disease | Not applicable | Recruiting
Sponsor: Asian Institute of Gastroenterology, India. Countries: India. Study locations: AIG Hospitals, Hyderabad; AIG Hospitals, Hyderabad. Registry last updated: 2026-06-17.
-
NCT05698017: hOMSC300 oral-mucosa stem cells for multiple system atrophy
Multiple system atrophy | Phase 1 | Active, not recruiting
Sponsor: Cytora Ltd.. Countries: Israel. Study locations: Tel-Aviv Sourasky Medical Center (Ichilov), Tel Aviv. Registry last updated: 2025-01-29.
-
NCT06951074: Autologous insulin-producing mesenchymal stem cells for type 1 diabetes
Type 1 diabetes | Phase 2 / Phase 3 | Recruiting
Sponsor: Ain Shams University. Countries: Egypt. Study locations: Children Hospital Eldemerdash, Cairo. Registry last updated: 2025-04-30.
-
NCT06344260: Neural stem-cell treatment for amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis | Phase 2 | Recruiting
Sponsor: Casa Sollievo della Sofferenza IRCCS. Countries: Italy. Study locations: 4 registry-listed locations; see official record for site status. Registry last updated: 2024-04-03.
-
NCT07367815: Allogeneic adipose-derived MSCs for mild to moderate Alzheimer disease
Alzheimer disease | Phase 1 / Phase 2 | Recruiting
Sponsor: University Hospital, Toulouse. Countries: France. Study locations: University Hospital of Toulouse, Toulouse. Registry last updated: 2026-06-23.
-
NCT04396899: iPSC-derived engineered human myocardium for terminal heart failure
Terminal heart failure | Phase 1 / Phase 2 | Recruiting
Sponsor: University Medical Center Goettingen. Countries: Germany. Study locations: University Medical Center Göttingen, Göttingen; Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen; University Medical Center Schleswig-Holstein, Lübeck. Registry last updated: 2026-02-20.
-
NCT05933434: Allogeneic mesenchymal stem cells for knee osteoarthritis
Knee osteoarthritis | Phase 1 / Phase 2 | Recruiting
Sponsor: Aarhus University Hospital. Countries: Denmark. Study locations: Aarhus University, Aarhus N. Registry last updated: 2024-06-11.
-
NCT06823713: RTX001 engineered macrophages for liver cirrhosis
Liver cirrhosis | Phase 1 / Phase 2 | Active, not recruiting
Sponsor: Resolution Therapeutics Limited. Countries: Spain + United Kingdom. Study locations: 15 registry-listed locations; see official record for site status. Registry last updated: 2026-10-05.
-
NCT05152290: Umbilical-cord or placental MSCs for spinal cord injury
Spinal cord injury | Phase 1 | Recruiting
Sponsor: The Foundation for Orthopaedics and Regenerative Medicine. Countries: Greece + United States. Study locations: Prodromos Stem Cell Institute, Naples; Prodromos Stem Cell Institute, Athens. Registry last updated: 2026-10-20.
-
NCT06564740: Umbilical-cord MSC transplantation in infants with biliary atresia
Biliary atresia and liver fibrosis | Not applicable | Unknown; registry update overdue
Sponsor: Necmi Kadıoğlu Hospital. Countries: Turkey (Türkiye). Study locations: Esenyurt State Hospital, Istanbul. Registry last updated: 2024-09-19.
-
NCT05306457: Neural progenitor cells secreting GDNF for ALS
Amyotrophic lateral sclerosis | Phase 1 | Active, not recruiting
Sponsor: Cedars-Sinai Medical Center. Countries: United States. Study locations: Cedars-Sinai Medical Center, Los Angeles. Registry last updated: 2025-08-19.
-
NCT04956744: Human embryonic-cell-derived MSCs for multiple sclerosis
Multiple sclerosis | Phase 1 | Active, not recruiting
Sponsor: ImStem Biotechnology. Countries: United States. Study locations: Shepherd Center, Atlanta; UMass Memorial Medical Center, Worcester; Rocky Mountain MS Clinic, Salt Lake City. Registry last updated: 2026-04-08.
Independent educational listing
The Regeneration Center is not a sponsor, investigator, recruiter or study site for any clinical trial shown in this curated set. Contact the study team through the official registry record to confirm recruitment, eligibility, risks, costs and participation details.
Read the official record before contacting a study
- Confirm the exact site: a study may be recruiting overall while an individual location is closed or not yet open.
- Review the inclusion criteria, exclusions, intervention, study phase and outcomes.
- Ask the study team about informed consent, alternatives, risks, costs, travel, privacy and withdrawal.
Official registry gateways
- WHO ICTRP Search Portal: Search records supplied by the WHO registry network and follow each result to its original registry.
- ClinicalTrials.gov: Search study status, sponsor, eligibility and individual study locations.
- CTIS public search: Current medicinal-product trials under the EU Clinical Trials Regulation.
- ISRCTN: Plain-language summaries, protocols, results and study outputs.
- ANZCTR: Interventional and observational studies with detailed recruitment filters.
- jRCT: Regulated studies including dedicated regenerative-medicine classifications.
- CRiS: Korean interventional and observational research in Korean and English.
- CTRI: Clinical studies conducted in India with phase and recruitment filters.
- TCTR: Clinical trials and observational research conducted in Thailand.
- ChiCTR: Search by condition, intervention, phase, city, hospital and recruitment status.
- ReBEC: Brazil-focused records available in Portuguese and English.
- PACTR: Pan-African trial search with country, status and map filters.
- DRKS: Interventional and observational studies with site and status search.
- IRCT: Iranian WHO Primary Registry with advanced search.
- REPEC: Authorized trials conducted in Peru, including historical records.
- SLCTR: Sri Lankan trial records with progress reports.
- Health Canada CTDB: Authorized Phase I–III pharmaceutical and biological drug trials; “ongoing” does not confirm recruitment.
Earlier research links: historical context
The following links were retained from an earlier version of this directory. They are not a current recruiting list or a statement of results. Some concern laboratory research rather than a clinical trial. Check the primary record before interpreting any study.
- Clinical study iPS cell therapy for eye disease
- ALS Clinical Trials
- Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure
- In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the B-Cell Specific Antigen CD19 Positive Residual Or Relapsed Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
- Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells
- Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant
- ALS and MND Stem Cell Trials at Emory University
- Autologous stem cell transplantation in adults with acute lymphoblastic leukemia
- In vitro differentiation of human placenta-derived multipotent cells into hepatocyte-like cells.
- Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells
- The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)
- Australian Clinical Trials
- Therapy for Peripheral Vascular Disease